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Abstract 
INTRODUCTION: Identifying at what point atrophy rates first change in Alzheimer’s 
disease is important for informing design of presymptomatic trials. 
METHODS: Serial T1-weighed MRI scans of 94 participants (28 non-carriers, 66 
carriers) from the Dominantly Inherited Alzheimer Network (DIAN) were used to 
measure brain, ventricular and hippocampal atrophy rates. For each structure, non-
linear mixed effects models estimated the change-points when atrophy rates deviate 
from normal and the rates of change before and after this point. 
RESULTS: Atrophy increased after the change-point, which occurred 1-1.5 years 
(assuming a single step change in atrophy rate) or 3-8 years (assuming gradual 
acceleration of atrophy) before expected symptom onset. At expected symptom 
onset, estimated atrophy rates were at least 3.6 times those before the change-point. 
DISCUSSION: Atrophy rates are pathologically increased up to seven years before 
“expected onset”. During this period, atrophy rates may be useful for inclusion and 
tracking of disease progression. 
 
 
Keywords: Longitudinal, Atrophy, Alzheimer's disease, Dementia, Autosomal 
dominant, Neuroimaging, MRI, Boundary Shift Integral, Non-linear modeling, 
Change-point  
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1. Background 
Testing potentially disease-modifying treatments for Alzheimer’s disease (AD) during 
the preclinical phase [1] presents challenges of recruitment and staging of 
asymptomatic individuals, as well as determining suitable measures for assessing 
disease modification. One recruitment strategy is to study members of families 
known to carry a pathogenic mutation in a gene – presenilin 1 (PSEN1), presenilin 2 
(PSEN2) or amyloid precursor protein (APP) – that causes autosomal dominant AD 
(ADAD). These mutations have almost 100% penetrance and ~50% of at-risk 
individuals are carriers. ADAD typically has an early and relatively predictable age at 
symptom onset [2,3]. The Dominantly Inherited Alzheimer Network (DIAN) is a 
multicentre observational study of individuals at risk of, or affected by, ADAD. DIAN 
performs longitudinal assessments of imaging, fluid biomarkers, and cognitive 
function, which reflect pathological features in ADAD [4] and sporadic AD [5]. In 
particular, cerebral atrophy measures derived from volumetric magnetic resonance 
imaging (MRI) are used as biomarkers of neurodegeneration and as outcome 
measures in trials [6].  
 
Longitudinal data from presymptomatic ADAD individuals provide a unique 
opportunity to determine when atrophy rates begin to diverge from normal. Previous 
cross-sectional, or small longitudinal studies report a wide range of estimates of this 
point of divergence: from 10 years before [4,7] to 7 years after [8] expected clinical 
onset (as determined by the affected parent’s age at onset).  
                                                        
Abbreviations: DIAN = Dominantly Inherited Alzheimer Network; ADAD = autosomal dominantly 
inherited familial AD; PSEN1 = presenilin 1; PSEN2 = presenilin 2; APP = amyloid precursor protein; EAO 
= expected age at onset; EYO = estimated years to expected symptom onset; NC = mutation non-carriers; 
pMut+ = presymptomatic mutation carriers; qMut+ = questionably or mildly symptomatic mutation 
carriers; sMut+ = overtly symptomatic mutation carriers. 
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We used serial MRI data from DIAN to model cerebral atrophy rates during 
presymptomatic and early symptomatic stages of ADAD. We assessed whole brain 
and hippocampal atrophy and ventricular expansion, three well-established imaging 
measures used as exploratory endpoints in clinical trials [6]. We hypothesize that 
presymptomatic carriers have similar atrophy rates to non-carriers up until a ‘change-
point’ when the biomarker starts to diverge from normal. This hypothesis is 
consistent with models of sporadic AD [5] that assume a sigmoidal trajectory, and 
cross-sectional findings from the DIAN cohort [4,7]. We used two non-linear mixed 
effects models (Supplementary Appendix A) to estimate the timing of change-points 
relative to expected symptom onset, and atrophy rates before and after these 
change-points. The first model assumes that the atrophy rate undergoes a single 
‘step change’ to a new, stable value; whereas the second model assumes a ‘gradual 
acceleration’ in atrophy rate after the change-point. These models help characterize 
when therapeutic effects on brain atrophy could potentially be observed in 
presymptomatic ADAD and could help focus future sample size calculations for 
upcoming prevention trials. 
 
2. Methods 
2.1 Participants and Procedures 
All participants were members of DIAN [9], and details of participating sites are 
available (http://dian-info.org/). The study received prior approval from appropriate 
Institutional Review Boards and Ethics Committees at each site. Informed consent 
was obtained from all participants. 
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Genotyping was performed to determine the presence of an ADAD mutation for each 
at-risk participant. A semi-structured interview assessed the expected age at onset 
(EAO), based on when the affected parent first showed progressive cognitive 
decline. Expected years to symptom onset (EYO) is the difference between age at 
scan and EAO [3]. Negative values indicate years before expected onset and 
positive values years after. 
 
At the sixth data freeze (July 2013), there were 102 participants with two or more 
MRI scans available and complete data (mutation status, age, EAO, and global 
Clinical Dementia Rating (CDR) score [10]).  
 
2.2 Volumetric MRI  
Volumetric T1-weighted scans were acquired on 3 Tesla MRI scanners using 
Alzheimer's Disease Neuroimaging Initiative (ADNI) standardized protocols [11] and 
corrected for intensity inhomogeneity [12]. Whole brain and hippocampal regions 
were automatically segmented [13–15]. Lateral ventricles were delineated semi-
automatically by an expert rater. Baseline volumetric measures were corrected for 
total intracranial volume (TIV), calculated using an automated technique [16]. For 
each structure, volume change was directly measured using a group-wise 
implementation [17–19] of the Boundary Shift Integral (BSI) [20] to ensure 
longitudinal consistency. A trained image analyst, blinded to participants’ mutation 
and clinical status, reviewed all raw and processed images. 
 
2.3 Clinical Classification 
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Participants were classified into four groups, based on mutation status, global CDR 
score, and actual age at onset (where this had occurred), determined by Uniform 
Data Set form B9, “Clinical Judgment of symptoms” [21]:  
 
 Mutation non-carriers (NC); our control group.  
 Presymptomatic mutation carriers (pMut+); included mutation carriers with 
a global CDR score of 0 at both their first two visits.  
 Questionably or mildly symptomatic mutation carriers (qMut+); included 
participants with at least one global CDR score of 0.5 during their first two 
visits, with the other visit being either 0 or 0.5. We excluded from this group 
participants who had a reported onset more than four years before study 
entry. 
 Overtly symptomatic mutation carriers (sMut+); included participants with 
a CDR score of 1.0 or greater at either (or both) of their first two visits or who 
were more than four years after reported onset at study entry.  
 
Eight participants were excluded from the analysis: seven (one NC, four pMut+, one 
qMut+, one sMut+) were identified during initial visual review of the image data and 
excluded due to non-Alzheimer’s pathology (e.g. infarct, neoplasm), imaging 
artifacts, or acquisition-related changes likely to result in unreliable atrophy 
measures. An additional participant (qMut+) was excluded due to moderate motion 
artefact on follow-up imaging and implausible growth in brain and hippocampi. As 
part of the sensitivity analysis, we re-ran the model including this participant 
(Supplementary Appendix B). 
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Two participants who initially satisfied the qMut+ criteria were retrospectively re-
classified as sMut+, as both participants had consistent evidence of cognitive decline 
over a sustained period.  
 
Our final sample therefore included 94 participants: 24 pMut+, 18 qMut+, 24 sMut+, 
and 28 NC. Of the 66 carriers, 54 had mutations in PSEN1, three in PSEN2, and 
nine in APP. There were 66 participants with two MR scans, 20 with three, and eight 
with four scans. The scan interval between baseline to follow-up ranged from 0.9 to 
3.3 years, and was independent of carrier status or clinical severity. Two participants 
(one qMut+ and one sMut+) had inadequate image quality for analyses involving 
hippocampi. 
 
2.4 Statistical analysis 
To compare baseline values between each of the three mutations groups (pMut+, 
qMut+, sMut+) and the non-carrier group, ANOVA models were used for age, EYO, 
and TIV, while logistic regression was used for APOE 4 positivity and sex. A 
generalized least squares linear regression model that allows different group-specific 
residual variances was used to compare baseline volumes (standardized to mean 
TIV) between each of the three carrier groups and non-carriers.  
 
The change-point model [22–24] was used to explore brain, ventricular and 
hippocampal atrophy rates (Supplementary Appendix A provides a detailed model 
description). As the focus of our study was the presymptomatic and earliest 
symptomatic stages of ADAD, the model included non-carriers (NC), 
presymptomatic, and questionably symptomatic carriers (pMut+/qMut+). 
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Figure 1 provides a schematic representation of the ‘step change’ and ‘gradual 
acceleration’ change-point models. In both, β represents the shared atrophy rate for 
NC and pMut+/qMut+ groups before the change-point, which takes place δ years 
before or after the EAO. Due to limited data, δ (for a specific brain structure) was 
assumed to be the same for all pMut+/qMut+ individuals. 
 
For the ‘step change’ model, γ is the change in atrophy rate for the pMut+/qMut+ 
group after the change-point. In the ‘gradual acceleration’ model, the atrophy rate for 
the pMut+/qMut+ group accelerates after the change-point by a value of 2γ per year. 
With each model, we estimated β, γ and δ for each region, and using these we 
estimated atrophy rates at various points before and after EAO.  
 
Our change-point model was not designed to estimate atrophy rates several years 
after symptom onset; to do so risked distorting a model that was designed to focus 
on the progression from early changes to clinical symptoms. Thus, a separate linear 
mixed-effects random-slopes model (with no change-point) was used to model 
atrophy rates of the sMut+ group, assuming all observations were after the change-
point.  
 
The change-point models are non-linear extensions of a previously described linear 
mixed-effects random-slopes model [25] (Supplementary Appendix A). Atrophy 
measures were log-transformed to provide symmetric approximations of percentage 
change from baseline. The change-point models were implemented using SAS 
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(version 9.4) procedure NLMIXED, which simultaneously estimated β, γ and δ. 
Robust estimates of uncertainty for these coefficients were obtained through 
bootstrapping [26,27], with 10,000 replicates and using bias corrected and 
accelerated (BCa) 95% confidence intervals. Sensitivity of the estimates and 
confidence intervals to outliers was explored (see Supplementary Appendix B).  
 
3. Results 
Table 1 summarizes demographic and clinical data. The sMut+ group was, as 
expected, older than the non-carriers, with smaller brain and hippocampal volumes, 
and larger ventricular volumes (all TIV-adjusted), reflecting pathological losses and 
larger TIV, which likely reflects the higher (albeit statistically non-significant) 
proportion of males in this group. The qMut+ group had smaller hippocampal 
volumes and larger ventricular volumes compared to non-carriers, while the preMut+ 
group just had smaller right hippocampal volumes. 
 
Table 2 shows the change-point model results for each structure. In the ‘step 
change’ model, the pre-change atrophy rate (β) was statistically significant in every 
structure except the right hippocampus. In all regions, there were significant 
increases in atrophy rate (γ) after the change-point. This is demonstrated by 
deriving, from the results of the model, a ratio between the atrophy rate at EAO (1-0 
years before) to the pre-change atrophy rate. This ratio was 4.0 for whole brain, 4.5 
for ventricles, and 9.0 for left hippocampus, but it could not be produced for right 
hippocampus as the estimated pre-change atrophy rate was small and not 
statistically significantly different from zero. However, the increase in atrophy rate (γ) 
after the change-point for the right hippocampus was larger than the corresponding 
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coefficient in the results for the left hippocampus. The estimated change-point () for 
brain, ventricle and left hippocampus was 1.4 years before EAO and 1.1 years 
before EAO for the right hippocampus. For whole brain and left hippocampus, the 
confidence intervals for  did not span zero, providing evidence that they occurred 
before EAO. Estimates of the ventricular change-point had greater uncertainty (−1.1 
to 13.5 years) than the other structures. Table 2 provides estimates for rates of 
change at various times before and after EAO. 
 
As with the ‘step change’ model, in the ‘gradual acceleration’ model all structures 
except the right hippocampus had statistically significant pre-change atrophy rates. 
All regions had coefficients (γ) indicating statistically significant increased 
neurodegeneration after the change-point. The ratio of atrophy rate at EAO to the 
pre-change rate was 3.6 for whole brain, 4.1 for ventricles, and 5.1 for left 
hippocampus. The ratio for the right hippocampus was also not available due to the 
small, non-significant pre-change atrophy rate, but the coefficient (γ) indicated that 
the right hippocampus had a similar increase towards neurodegeneration as the left. 
The change-point estimates () for the whole brain and ventricles were 3.0-4.6 years 
earlier than for the hippocampi. For all structures, the confidence intervals for  did 
not span zero. Figure 2 shows estimated atrophy rates and 95% confidence intervals 
from both models in relation to EYO.  
 
In the sensitivity analysis, we re-ran the model including the participant with 
movement artefact and clinically implausible data (Supplementary Appendix B). The 
pattern of the results was not materially altered although the statistical significance of 
some parameter estimates was lost.  
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The estimated rates of change in sMut+ participants were approximately double 
those found in pMut+/qMut+ carriers at EAO using the change-point models. The 
symptomatic rates were: −2.41% (95% CI: −2.88, −1.95) per year for whole brain, 
15.0% (95% CI: 12.6,17.5) for ventricles, −4.70% (95% CI: −6.39, −3.01) for left 
hippocampus, and −4.64% (95% CI: −5.68, −3.60) for right hippocampus. 
 
4. Discussion  
The goal of this study was to estimate when brain, ventricular and hippocampal 
volume changes in ADAD diverge from non-carriers, and to model the rates before 
and after this transition using serial MRI data from the DIAN cohort.  We designed 
two non-linear mixed effects models: one assuming a single ‘step-change’ and 
another assuming a ‘gradual acceleration’ in rates of atrophy after the change-point. 
This type of model has previously been used to investigate the trajectories of 
cognitive decline [23,28] and atrophy rates [29,30]. In all cases, there was evidence 
of increased atrophy after the change-point, suggesting that our models better reflect 
the non-linear nature of atrophy in early-stage disease than a linear relationship 
would. The 'gradual acceleration' model found evidence for all assessed regions that 
atrophy rates diverge from normal values before symptom onset, with the change-
point occurring 3.0 to 7.6 years before EAO. The ‘step change’ model found a 
change-point of 1.4 years before EAO for whole brain and left hippocampus but was 
unable to show evidence of a change-point preceding EAO for ventricles or right 
hippocampus.  
 
4.1 Interpreting the change-point model results 
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A key advantage of using two different change-point models is that they provide 
complementary information about the timing of the change-point. The ‘step change’ 
model provides the most conservative estimate of when atrophy rates diverge. In 
contrast, the ‘gradual acceleration’ model is probably more biologically plausible, 
based on previous results in ADAD [4,7,31,32] and by the well-characterised spatial 
spread of neurodegeneration [33] that typically begins in the medial temporal lobe 
and gradually spreads into neocortical regions. However, there are caveats to the 
gradual acceleration model used. The non-linear nature of the atrophy may vary 
between individuals and a quadratic may not be the most appropriate fit. However, 
given the size of the dataset, this approach minimizes risk of overfittings. Change-
point models also avoid some of the pitfalls that can occur when including polynomial 
terms in a linear regression to model this non-linear relationship [34]. While a 
quadratic term could better capture the increase in atrophy rate observed around 
expected onset, it may also produce artefacts of increased atrophy in carriers who 
are decades before their expected onset. 
 
Unlike linear models, change-point models can capture the different phases of 
atrophy/expansion during the long period of presymptomatic disease progression. 
Both models provide similar estimates of β (see Table 2), the pre-change atrophy 
rate.  This suggested age-related changes broadly consistent with previous aging 
studies [35–37] showing small but significant rates of whole-brain atrophy of the 
order of 0.2-0.6%/year and hippocampal atrophy of the order of 0.3-0.4%/year for 
similar age ranges to this cohort.  From both models, there was evidence of 
increased atrophy after the change-point in all regions.  
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4.2 Estimating onset of pathological atrophy 
It is unclear when disease-related atrophy first becomes evident in ADAD. Cross-
sectional results from PSEN1 E280A mutation carriers [38,39] and DIAN [4,7] 
suggest atrophy of hippocampi diverge from non-carriers ~6 years and 10 years 
before symptom onset, respectively; earlier than in our models. However, initial 
longitudinal results from DIAN [7] (N=53) identified increased atrophy rates only in 
symptomatic carriers. A study of 13 presymptomatic PSEN1 carriers found increased 
cortical thickness at baseline but subsequent thinning of a number of cortical regions 
[40], suggesting a non-linear nature to presymptomatic changes – with grey matter 
increases preceding declines. 
 
Most previous longitudinal volumetric MRI studies of ADAD mutation carriers have 
been relatively small, single-site studies. One study following presymptomatic 
participants to clinical onset indicated pathological hippocampal atrophy rates 
appeared ~5.5 years before AD diagnosis [31]. Weston et al. [41] examined cortical 
thickness longitudinally in presymptomatic carriers and detected significant losses in 
the precuneus eight years before EAO. These values are consistent with our findings 
using a gradual acceleration model where the change point was 7.6 years before 
onset. However, another study of 16 ADAD mutation carriers (seven with long-term 
follow-up) did not detect structural MRI changes until after symptom onset [8], 
suggesting that a heterogeneity in these small cohorts and the methods used to 
analyze them may generate markedly different results.  
 
No prior ADAD study has used change-point models, making it difficult to compare 
estimates. However, there are similarities between our findings and sporadic AD 
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studies that used similar approaches. A study of 79 elderly patients, 37 of whom 
developed mild cognitive impairment (MCI), reported a ventricular expansion 
change-point 2.3 years before MCI diagnosis [29]. Another longitudinal study 
(N=296, 66 progressing to MCI) found a similar hippocampal atrophy change-point of 
2-4 years before clinical onset [30]. Their estimate of a 0.2% per year pre-change 
hippocampal atrophy rate accords with ours (0.2% left, 0.1% right). Their post-
change atrophy rate estimate for the right hippocampus (2.7%/year) was similar to 
our value (2.5%) whereas their left hippocampal rate estimate (1.2%) was lower than 
our (2.1%).  
 
4.3 Predicting clinical onset in ADAD 
An important challenge is what estimate to use for clinical onset before it has 
occurred. Many studies, including ours, use an EAO based on when the affected 
parent first developed symptoms consistent with progressive decline. Other 
measures are based on the average across all previously affected family members, 
or the reported age at onset in the literature for a particular mutation [3]. However, 
each is an imperfect estimate of the future age at onset.  
 
If future clinical trials use EYO as an inclusion criterion, then it is the distribution of 
atrophy rates relative to EAO that is of importance. However, if we wish to 
understand the etiology of the disease, then the distribution of atrophy rates relative 
to actual onset is more informative, as change-points are likely to be more strongly 
related to actual rather than expected age at onset. The effect of switching from 
actual to expected onset in statistical models will change the form of the estimated 
volume change over time, smoothing it to some degree. Without knowledge of actual 
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onset, this effect is not easily avoided. We did, however, attempt to reduce its impact 
by excluding overtly symptomatic carriers from our change-point models.  
 
Identifying precisely when clinical onset has occurred is not straightforward. To 
facilitate standardization across sites, DIAN rigorously monitors how raters perform 
CDR and other assessments [42].  In at-risk individuals, other factors can influence 
cognitive function or behavioral changes, including stress, anxiety, and the constant 
level of vigilance and introspection that participants experience. In this study, there 
were six qMut+ participants who reverted from a baseline global CDR of 0.5 to 0 at 
follow-up. These cases highlight the subtle nature of transitions from unimpaired to 
“affected” and the potential confounds of mood disturbance and other factors. We 
addressed this uncertainty by including questionably or mildly symptomatic carriers 
in our change-point models.  
 
4.4 Limitations and future work 
Change-point models have been used to model atrophy rates in preclinical sporadic 
AD [29,30]. We expand on these approaches by adapting the model for repeated 
measures of direct change instead of individual volumetric measures and allowing 
for either a ‘step change’ or ‘gradual acceleration’ after the change-point. Due to the 
non-linear nature of our models, and the use of bootstrapping to obtain confidence 
intervals for the model coefficients, these models are susceptible to influential 
outliers, especially with smaller sample sizes (see the sensitivity analysis in 
Supplementary Appendix B). Additional longitudinal data should provide improved 
robustness against such issues.  
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No prior study has characterized the progression of atrophy in such a large cohort of 
presymptomatic and earliest symptomatic ADAD. DIAN is currently recruiting 
participants into a multicentre clinical trial [43], and the samples from our analysis 
should more closely reflect a clinical trial setting. Whole brain, lateral ventricles, and 
hippocampi are the most studied structures in sporadic AD, and are often used as 
trial outcome measures. From the results, these atrophy measures appear to be 
elevated compared to non-carriers approximately 5 years before expected onset, 
making them best suited for prevention trials in ADAD from this period onward. 
Given the evidence of presymptomatic atrophy in specific cortical regions [40,41], 
future application of the change-point model could involve studying atrophy rates of 
specific cortical structures, such as the precuneus and posterior cingulate. Atrophy in 
these structures may appear earlier and thus be better suited for trials that target 
presymptomatic patients.  In addition, the model should incorporate information from 
other biomarkers, including CSF amyloid and tau concentrations, to determine how 
markers of these pathologies affect the timing of the change-point. Finally, it is 
essential to understand which preclinical changes in ADAD generalize to sporadic 
AD, as differences in the structures preferentially affected appear to exist [44].  
 
4.5 Conclusions 
Atrophy rates increase in ADAD some years before expected symptom onset. Using 
two different change-point models, we can characterize when this change occurs. 
The ‘step-change’ model provides a minimum estimate, 1.4 years before expected 
onset. The ‘gradual acceleration’ model provides a more biologically plausible 
approach towards how atrophy rates diverge from normal, with brain atrophy rates 
showing pathological acceleration ~7.6 years before expected onset and 
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hippocampal rates changing ~3.0 years before expected onset. These models may 
help predict the time to clinical onset for presymptomatic individuals with increased 
atrophy and identify individuals for prevention trials.  
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Figure captions 
 
Figure 1: Schematic representation of the ‘step change’ (Figure 1a) and 
‘gradual acceleration’ (Figure 1b) change-point models. 
 
Figure 2: Rates of change estimated from the ‘step change’ and ‘gradual 
acceleration’ models, as a function of the estimated years from symptom 
onset (EYO) for the pMut+/qMut+ carriers. 
The figure shows the relationship between rate of annualized volume change (%) 
and EYO. 95% confidence intervals are included, computed from the bootstrap 
samples. While the schematics in Figure 1 display the decline in actual volume, 
these graphs represent the rate of change in volume. A horizontal line indicates the 
estimated atrophy rate (from the ‘step change’ model) for non-carriers and carriers 
before the change-point before any deviation from normal rates of change. Vertical 
dotted lines indicate the change-points for both the ‘step change’ and ‘gradual 
acceleration’ models. For periods that include the change-point, the estimated rate of 
atrophy is a weighted combination representing the transition from the pre-change-
point atrophy to the post-change-point atrophy. Top left: whole brain; top right: lateral 
ventricles; bottom left: left hippocampus; bottom right: right hippocampus.  
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Table 1 
Baseline demographics and region volumes for participants included in the 
longitudinal analysis. 
 Non-carriers 
(NC) 
Presymptomatic 
mutation carriers 
(preMut+) 
Questionably 
or mildly 
symptomatic 
mutation 
carriers 
(qMut+) 
Overtly 
symptomatic 
mutation 
carriers 
(sMut+) 
N 28 24 18 24 
Age, yrs (SD)  41.0 (8.4) 37.7 (10.1) 39.1 (10.2) 48.6 (8.2)§ 
Sex, F/M 17/11 16/8 11/7 10/14 
APOE status, 
No. (%)* 
6/28 (21%) 7/24 (29%) 6/18 (33%) 7/24 (29%) 
Expected 
years to 
onset (EYO), 
yrs (SD)† 
−5.52 (8.62) −8.05 (8.38) −4.19 (5.76) 4.01 (6.46)§ 
TIV, ml 
(SD) 
1374 (129) 1373 (142) 1416 (124) 1483 (164)§ 
Brain 
volume, ml‡ 
(95% CI) 
1178  
(1163, 1194) 
1182  
(1162, 1201) 
1163 
(1142, 1184) 
1055§  
(1028, 1081)  
Ventricular 
volume, ml‡ 
(95%CI) 
15.2  
(13.0, 17.46) 
15.4 
(12.5, 18.3) 
20.0§ 
(15.9, 24.0) 
34.3§  
(28.5, 40.1)  
Left 
hippocampal 
volume, ml‡ 
(95% CI) 
3.01  
(2.91, 3.10) 
2.90 
(2.79, 3.00) 
2.73§ 
(2.62, 2.84) 
2.45§  
(2.28, 2.61) 
Right 
hippocampal 
volume, ml‡ 
(95% CI) 
3.08  
(2.99, 3.17) 
2.93§ 
(2.82, 3.01) 
2.76§ 
(2.63, 2.89) 
2.55§  
(2.37, 2.73) 
 
*Number (%) with APOE genotype 24, 34 or 44. †A negative value of EYO indicates 
that a participant joined the study before their expected age of onset, based on 
parental age at onset; EYO values for non-carriers are only indicative; EYO values 
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for overtly symptomatic mutation carriers do not reflect clinically determined actual 
age of onset. ‡Regional volumes were standardized to the mean TIV using a linear 
regression model. §p<0.05 vs. NC. 
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Table 2a  
Rates of change in whole brain and ventricular atrophy measures estimated using the step change and gradual 
acceleration change-point models.  
 
 
Whole brain Lateral ventricles 
 
Step change Gradual acceleration Step change Gradual acceleration 
Annualized rate of pre-change 
atrophy (95% CI) 
−0.28% 
(−0.42, −0.18) 
−0.25% 
(−0.37, −0.11) 
1.79% 
(0.44, 3.58) 
1.59% 
(0.53, 2.91) 
Post-change coefficient*  
(95% CI)  
−0.84% 
(−1.22, −0.32) 
−0.05 
(−0.11, −0.01) 
6.29% 
(1.99, 9.18) 
0.45 
(0.16, 1.17) 
Change-point years before onset 
(95% CI) 
1.4 
(0.5, 3.8) 
7.6 
(2.3, 14.8) 
1.4 
(−1.1, 13.5) 
6.0 
(2.0, 15.5) 
Atrophy rate 
(95% CI) 
10-9 years 
before 
−0.28% 
(−0.42, −0.18) 
−0.25% 
(−0.39, −0.10) 
1.79% 
(0.44, 3.58) 
1.59% 
(0.44, 3.28) 
 
9-8 years before 
−0.28% 
(−0.42, −0.18) 
−0.25% 
(−0.38, −0.10) 
1.79% 
(0.44, 3.58) 
1.59% 
(0.43, 3.41) 
 
8-7 years before 
−0.28% 
(−0.42, −0.18) 
−0.26% 
(−0.38, −0.10) 
1.79% 
(0.44, 3.58) 
1.59% 
(0.43, 3.11) 
 
7-6 years before 
−0.28% 
(−0.42, −0.18) 
−0.35% 
(−0.66, −0.21) 
1.79% 
(0.44, 3.58) 
1.59% 
(0.26, 2.75) 
 
6-5 years before 
−0.28% 
(−0.46, −0.18) 
−0.44% 
(−0.77, −0.25) 
1.79% 
(0.46, 3.60) 
2.02% 
(0.64, 4.03) 
 
5-4 years before 
−0.28% 
(−0.68, −0.18) 
−0.53% 
(−0.86, −0.27) 
1.79% 
(0.41, 3.57) 
2.92% 
(1.20, 5.73) 
 33 
 
4-3 years before 
−0.28% 
(−0.79, −0.15) 
−0.62% 
(−0.95, −0.30) 
1.79% 
(0.30, 3.77) 
3.82% 
(1.49, 6.57) 
 
3-2 years before 
−0.28% 
(−1.15, −0.14) 
−0.72% 
(−1.04, −0.36) 
1.79% 
(0.30, 4.18) 
4.72% 
(2.00, 7.41) 
 
2-1 years before 
−0.64% 
(−1.21, −0.20) 
−0.81% 
(−1.16, −0.48) 
4.51% 
(1.82, 9.64) 
5.62% 
(3.17, 8.34) 
 
1-0 years before 
−1.12% 
(−1.54, −0.66) 
−0.90% 
(−1.27, −0.59) 
8.07% 
(3.27, 15.24) 
6.52% 
(4.34, 9.46) 
 
0-1 years after 
−1.12% 
(−1.52, −0.63) 
−0.99% 
(−1.39, −0.64) 
8.07% 
(3.00, 14.70) 
7.42% 
(4.93, 10.53) 
 
1-2 years after 
−1.12% 
(−1.52, −0.64) 
−1.09% 
(−1.53, −0.66) 
8.07% 
(3.18, 10.90) 
8.33% 
(5.39, 11.85) 
 
2-3 years after 
−1.12% 
(−1.52, −0.64) 
−1.18% 
(−1.70, −0.67) 
8.07% 
(3.50, 11.01) 
9.23% 
(5.76, 13.66) 
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Table 2b 
 
Rates of change in left and right hippocampal atrophy measures estimated using the step change and gradual 
acceleration change-point models. 
 
 
Left hippocampus Right hippocampus 
 
Step change Gradual acceleration Step change Gradual acceleration 
Annualized rate of pre-change atrophy 
(95% CI) 
−0.23% 
(−0.44, −0.03) 
−0.28% 
(−0.49, −0.07) 
−0.07% 
(−0.24, 0.13) 
−0.08% 
(−0.24, 0.13) 
Post-change coefficient*  
(95% CI) 
−1.82% 
(−3.28, −1.06) 
−0.21 
(−0.51, −0.12) 
−2.42% 
(−6.45, −1.56) 
−0.29 
(−0.86, −0.15) 
Change-point years before onset 
(95% CI) 
1.4 
(0.9, 1.8) 
3.2 
(2.0, 5.8) 
1.1 
(−2.0, 1.8) 
3.0 
(1.5, 6.2) 
Atrophy rate 
6-5 years before 
−0.23% 
(−0.44, −0.03) 
−0.28% 
(−0.51, −0.07) 
−0.07% 
(−0.24, 0.13) 
−0.08% 
(−0.25, 0.14) 
5-4 years before 
−0.23% 
(−0.44, −0.03) 
−0.28% 
(−0.58, −0.05) 
−0.07% 
(−0.24, 0.13) 
−0.08% 
(−0.28, 0.16) 
4-3 years before 
−0.23% 
(−0.45, −0.03) 
−0.28% 
(−0.65, 0.01) 
−0.07% 
(−0.24, 0.13) 
−0.08% 
(−0.30, 0.21) 
 
3-2 years before 
−0.23% 
(−0.46, −0.03) 
−0.57% 
(−1.36, −0.18) 
−0.07% 
(−0.25, 0.13) 
−0.39% 
(−1.19, −0.02) 
2-1 years before 
−1.02% 
(−2.15, −0.19) 
−0.99% 
(−1.82, −0.47) 
−0.29% 
(−1.75, 0.20) 
−0.98% 
(−1.75, −0.40) 
1-0 years before 
−2.06% 
(−3.43, −1.28) 
−1.42% 
(−2.40, −0.81) 
−2.49% 
(−4.10, −1.79) 
−1.57% 
(−2.37, −1.00) 
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0-1 years after 
−2.06% 
(−3.52, −1.29) 
−1.84% 
(−3.22, −1.14) 
−2.49% 
(−4.85, −1.64) 
−2.16% 
(−3.40, −1.45) 
 
1-2 years after 
−2.06% 
(−3.52, −1.29) 
−2.27% 
(−4.19, −1.44) 
−2.49% 
(−5.81, −1.64) 
−2.74% 
(−4.80, −1.86) 
 
2-3 years after 
−2.06% 
(−3.52, −1.30) 
−2.69% 
(−5.20, −1.74) 
−2.49% 
(−6.74, −1.65) 
−3.33% 
(−6.51, −2.23) 
 
 
*For the ‘step change’ model, the post-change coefficient parameter o the model, γ, represents the change to the atrophy rate for 
presymptomatic and early symptomatic carriers after the change-point, and has units of percentage per year. In the ‘gradual 
acceleration’ model, the post-change coefficient is proportional to the rate of acceleration in the atrophy rate after the change-point. 
Due to this coefficient representing a time-squared term in the model, the rate of acceleration after the change point is a value of 2γ 
per year. This coefficient has units of percentage per year squared. 
 
 
 36 
 
Figure 1(A) 
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Figure 1(B) 
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Figure 2
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Supplementary Appendix A: Statistical methods and model development 
 
The ‘step change’ version of the change-point model can be described by: 
log (
𝑉𝑜𝑙𝑖𝑗 + 𝛥𝑉𝑜𝑙𝑖𝑗𝑘
𝑉𝑜𝑙𝑖𝑗
) =  (𝛽 + 𝑏𝑖)(𝑎𝑔𝑒𝑖𝑘 −  𝑎𝑔𝑒𝑖𝑗)  +   
𝛾 ([𝑎𝑔𝑒𝑖𝑘 − (𝐸𝐴𝑂𝑖 − 𝛿)]
+ −  [𝑎𝑔𝑒𝑖𝑗 − (𝐸𝐴𝑂𝑖 − 𝛿)]
+
  ) +  𝑢𝑖𝑘 − 𝑢𝑖𝑗 + 𝜂𝑖𝑗𝑘 
where, X+ = X if X≥0 
      = 0 if X<0 
      = 0 for the NC group 
and bi ~ N(0,𝜎𝑏
2);  uij ~ N(0,𝜎𝑢
2);  uik ~ N(0,𝜎𝑢
2);  ηijk ~ N(0,𝜎𝜂
2). 
(A.1) 
Each observation for subject i includes measurements from two of the visits, the 
baseline visit (j) and one of the follow-up visits (k), at ageij and ageik respectively, 
with the measure of volume change between the two visits being the direct BSI 
measure ΔVolijk. All pairs of visits included the first (baseline) visit so there is only 
one choice of j but there is potentially more than one k (as some participants had 
more than two visits in total). In these models, EYOij = ageij – EAOi. The change-
point terms X+ allow only volume changes from pMut+/qMut+ participants with at 
least one scan visit within δ years of EAO to contribute to the estimation of γ. 
Individual variations in atrophy rate and between visits were included as random 
effects; bi is the random subject specific deviation from the average atrophy rate 
(before the change-point); uij and uik are random subject specific deviations from the 
fixed effects at the baseline and follow-up visits respectively; ηijk is the residual error. 
The ‘gradual acceleration’ version of the change-point model was obtained by 
squaring each of the X+ terms.  
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log (
𝑉𝑜𝑙𝑖𝑗 + 𝛥𝑉𝑜𝑙𝑖𝑗𝑘
𝑉𝑜𝑙𝑖𝑗
) =  (𝛽 + 𝑏𝑖)(𝑎𝑔𝑒𝑖𝑘 −  𝑎𝑔𝑒𝑖𝑗)  +   
   𝛾 (([𝑎𝑔𝑒𝑖𝑘 − (𝐸𝐴𝑂𝑖 − 𝛿)]
+)2 − ([𝑎𝑔𝑒𝑖𝑗 − (𝐸𝐴𝑂𝑖 − 𝛿)]
+
)
2
 ) + 𝑢𝑖𝑘 − 𝑢𝑖𝑗
+ 𝜂𝑖𝑗𝑘 
where, X+ = X if X≥0 
                 = 0 if X<0 
                 = 0 for the NC group 
and bi ~ N(0,𝜎𝑏
2);  uij ~ N(0,𝜎𝑢
2);  uik ~ N(0,𝜎𝑢
2);  ηijk ~ N(0,𝜎𝜂
2).   
(A.2) 
 
                
During the development of the change-point models, we implemented the model in 
two different statistical packages: SAS and Stata (version 14.1), to check that we 
were getting consistent estimates from both. The results from the parallel Stata 
analyses for the ‘step change’ and ‘gradual acceleration’ change-point models were 
broadly consistent with the SAS results throughout, and have not been reported: 
they were subject to greater constraints than the SAS NLMIXED approach. In Stata, 
we used a ‘two-stage’ mixed effects modeling approach, where we first estimated δ, 
based on the profile likelihood, and then fixed this estimate for the model to 
determine β and γ, in line with an approach taken by many implementations of 
change point models [1-3]; confidence intervals for all parameters were obtained 
through bootstrapping.  
 
Implementing the change-point models using SAS (version 9.4) procedure NLMIXED 
allowed us to estimate β, γ and δ in one process. The estimate of δ was restricted so 
that the change-point could not be later than two years after EAO; this was to ensure 
that a reasonable number of observations, at least 10, contributed to the estimation 
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of γ. When running the SAS analyses, the Nelder-Mead Simplex Optimization 
method was used, which does not require either first-order or second-order 
derivatives and does not assume that the objective function has continuous 
derivatives [4]. As non-linear models can be sensitive to parameter initialization [5], 
the parameter values for NLMIXED were initialized based on point estimates 
obtained from the parallel analyses using Stata. This initialization method also 
reduced computational time [6].  
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Supplementary Appendix B: Sensitivity analysis 
 
 
Sensitivity analysis was performed using the jackknife command in Stata. Each 
replicate of the jackknife removed all observations from a single participant: if they 
had only two time points and only one atrophy measurement, only one observation 
was removed. If they had more than two time points and thus multiple observations, 
all of these were removed in the jackknife replicate. Upon visual review of the scans 
and the measurements, for one participant there were biologically implausible 
measurements of change (large brain and hippocampal growth, shrinking ventricles) 
that appeared to be the result of movement in the follow-up scans compared to the 
baseline. When included in the sensitivity analysis, the resulting estimates from the 
jackknife replicate from this participant resulted in significantly modified estimates to 
the model compared to the rest of the replicates, indicating that it was acting as an 
influential point. This participant was removed from the dataset for the main analysis 
but we also repeated all of the analyses including this participant in order to 
investigate the sensitivity of the model design to an outlier. The following tables B.1 
and B.2 are analogues of Tables 2(a) and (b) in the main paper for the analyses, but 
for analyses that include this participant.  
 
We also performed some sensitivity analyses on the initialization of the parameters 
for the non-linear models. First we obtained profile plots of log likelihood with respect 
to a plausible range of parameter values to gain a sense of the smoothness of the 
optimization function with respect to the parameters, the approximate location of the 
global maximum, and the presence of any local maxima. Then we ran the model 
multiple times using different initialization settings. In all models, the results were 
relatively unchanged over a wide range of initial values for beta and gamma. The 
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parameter that was most sensitive to initialization was the delta parameter 
representing the change-point. Depending on the initial value for delta, the model 
appeared to reach different results for whole brain and ventricles in the step change 
model and for ventricles in the gradual acceleration model. In some cases, the 
estimate for delta deviated by 1-4 years from that obtained with the initialization 
settings used in the models that we report in the paper. However, in all cases, our 
initialization strategy – of basing the starting values on the results from the two-step 
approach in the Stata based model – resulted in obtaining the global (log likelihood) 
maximum. The different results obtained by perturbing the initialization values were 
due to the model becoming stuck in a local maximum. Our models’ parameter 
estimates for left and right hippocampi did not appear sensitive to parameter 
initialization. 
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Supplementary Table B.1  
Rates of change in whole brain and ventricular atrophy measures estimated using the step change and gradual 
acceleration change-point models including the participant with clinically implausible volume change data and motion 
artifact on followup imaging. 
  Whole brain Lateral Ventricles 
 
Step Change 
Gradual 
Acceleration 
Step Change Gradual Acceleration 
Annualized rate pre-change-point 
(95% CI) 
−0.28% 
(−0.43, −0.18) 
−0.25% 
(−0.40, −0.13) 
1.91% 
(0.32, 3.56) 
1.67% 
(0.58, 3.05) 
Post-change-point coefficient*  
(95% CI)  
−0.68 
(−1.10, −0.18) 
−0.03 
(−0.09, −0.01) 
5.11 
(−2.36, 8.21) 
0.31 
(−0.28, 0.82) 
Change-point years before onset 
(95% CI) 
1.6 
(0.5, 4.1) 
8.6 
(3.2, 18.8) 
1.4 
(−1.2, 13.2) 
7.2 
(2.1, 19.8) 
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Supplementary Table B.2 
 
Rates of change in left and right hippocampal atrophy measures estimated using step change and gradual acceleration 
change-point models including the participant with clinically implausible volume change data and motion artifact on 
followup imaging. 
 Left hippocampus Right hippocampus 
 
Step Change 
Gradual 
Acceleration 
Step Change Gradual Acceleration 
Annualized rate pre-change-point 
(95% CI) 
−0.22% 
(−0.43, −0.02) 
−0.31% 
(−0.57, −0.11) 
−0.09% 
(−0.28, 0.08) 
−0.10% 
(−0.30, 0.10) 
Post-change-point coefficient*  
(95% CI) 
−1.49 
(−2.56, −0.53) 
−0.11 
(−0.27, 0.60) 
−1.86 
(−3.14, −0.82) 
−0.17 
(−0.38, −0.02) 
Change-point years before onset 
(95% CI) 
1.8 
(1.1, 2.4) 
4.5 
(2.3, 14.1) 
1.4 
(−0.1, 2.0) 
4.3 
(2.2, 13.0) 
 
* For the ‘step change’ model, the post-change coefficient parameter o the model, γ, represents the change to the atrophy rate for 
presymptomatic and early symptomatic carriers after the change-point, and has units of percentage per year. In the ‘gradual 
acceleration’ model, the post-change coefficient is proportional to the rate of acceleration in the atrophy rate after the change-point. 
Due to this coefficient representing a time-squared term in the model, the rate of acceleration after the change point is a value of 2γ 
per year. This coefficient has units of percentage per year squared.
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